Jared Jewelers and St. Jude

Since 1999, Jared Jewelers and our customers have proudly supported St. Jude Children's Research Hospital®, raising more than $122 million to help make cures possible for kids with cancer.
Building on this legacy of impact, Jared and our parent company, Signet Jewelers, have committed $100 million to further advance lifesaving research, treatment and care for children at St. Jude.
Store employee with St. Jude bear
Capri and her father

How Your Donation Helps

Zero Financial Burden for Care

Families never receive a bill from St. Jude for treatment, travel, housing or food—so they can focus on helping their children live.

Increasing Survival Rates

When St. Jude opened in 1962, childhood cancer was considered incurable. Since then, St. Jude has helped push the overall survival rate in the U.S. from 20% to more than 80%.

Helping Children Worldwide

St. Jude cares for some of the world's sickest children regardless of their race, ethnicity, beliefs, or ability to pay.

We Make an Impact: Jared Inspires Love for St. Jude

Together, Jared team members and customers help turn everyday moments of generosity into meaningful support for children and families at St. Jude Children’s Research Hospital®. Through donations made in stores and online, the annual holiday plush campaign, and team member-led fundraising, the Jared community helps empower the groundbreaking research St. Jude shares with doctors and researchers around the world to find more cures and make better treatments possible.
Kay Jewelers building on St. Jude campus
Inside children's health care unit
Inside lobby of St. Jude's facility
Inside St. Jude's children's facility
Slater, St. Jude patient

Meet Slater

Slater was 4 in 2018 when he was diagnosed with neuroblastoma, a pediatric cancer that develops in certain types of nerve tissue. It was stage IV and spreading. At the time, five-year survival rates for neuroblastoma had been around 50% for a decade.
Slater was referred to St. Jude Children's Research Hospital®, where he fit the criteria for a clinical trial for patients with newly diagnosed, high-risk neuroblastoma. Using an approach called immunotherapy, this clinical trial aimed to find out if adding a specific antibody to the first rounds of chemotherapy could improve outcomes in children with neuroblastoma by helping the body target and kill the cancer cells. Treatment included chemotherapy, immunotherapy, proton beam radiotherapy and a bone marrow transplant.

Now in middle school, Slater attended his first dance, placed second in the science fair and discovered a love of digital media and animation. He likes to cook, play basketball and football, play video games, fish, ski, ice skate and hang out with his older brother, Sawyer.
St. Jude | Jared